Report Overview

The global viral antigens market was pegged at US$ 0.123 billion in 2021 and is expected to witness a CAGR of 10.0% during the forecast period.

Market Fundamentals 

All species of life, including plants, animals, archaea, and bacteria, are susceptible to virus infection. A virus's release of a toxin or other hazardous substance, known as an antigen, causes its host to develop an immune response. A viral protein is an antigen recognised by the viral genome and capable of being identified by a specific immune response. IFA and ELISA are used to identify viral antigens in neutrophils and platelets from bone marrow or blood as well as in serum, saliva, tears, and plasma. The stage of an infection can also be determined by nucleic amplification testing. Antigens should be measured using serum or blood testing to produce the best results.

Market Dynamics

[865942]

The rising use of viral antigens in vaccine development, as well as improvements in image analysis software and informatics platforms for viral antigen detection, are all attributed with driving the viral antigens market. Furthermore, the introduction of highly developed technology platforms for vaccine research and the rise in viral protein R&D efforts continue to be the main growth drivers of the market for viral antigens. Significant efforts to provide rapid diagnostic tools and vaccinations against the new coronavirus will further boost the market's future growth. 

Moreover, one of the current developments in viral antigen technology is the electron microscopy workflow. It has the ability to pinpoint where antigens are located in viruses and vaccines. The market is expected to rise as researchers become more aware of the benefits of utilising this technology in vaccine research. However, recombinant viral antigens may experience a decline in demand in the near future since they are less immunogenic than inactivated whole-virus vaccines.

Market Ecosystem

The global viral antigens market has been analysed into fur perspectives by diagnosing techniques, product type, end user and region

Viral Antigens Market by Diagnosing Techniques

[8765489]

Based on diagnosing techniques, the global viral antigens market has been segmented into molecular diagnostics-based methods, immunoassay-based methods, mass spectroscopy-based method, and others. The molecular diagnostics-based techniques have been sub segmented into PCR based, NGS based and ELISA. During the forecast period, the molecular diagnostics-based method dominated the global viral antigen market owing to its expanding use in determining viral antigens.

Viral Antigens Market by Product Type

Based on product type, the global viral antigens market has been segmented into instruments, assay kits, and consumables. The Instruments segments dominated during forecast period owing to increasing usage of the instrument in R&D sector and rising cost of instrument will drive the market. However, assay kits will have also showed a lucrative growth during forecast period.

Viral Antigens Market by End User

Based on end user, the global viral antigens market has been segmented into hospitals, diagnostic centers/laboratories, blood banks and others.  The diagnostics centers segment dominates the global viral antigen market during forecast period. In a laboratory, clinical specimen tests are carried out to gather data on the patient's health to aid in the diagnosis, treatment, and prevention of disease. The services provided by viral diagnostic laboratories and their function in the clinical care of patients have undergone a substantial revolution during the past few decades.

Viral Antigens Market by Region

Based on region, the global viral antigens market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. The North American region dominated the market during forecast period because of the existence of national institutes supporting biotechnology and life science research, growth in the pharmaceuticals industry, and an increase in the number of drug approvals throughout the region are likely to fuel market growth. For instance, according to the World Health Organization's International Clinical Trials Registry Platform (ICTRP), high-income countries filed 29,538 clinical trials annually in 2020, up from 21,028 in 2010.

However, Europe is predicted to have the second-highest market growth due to the strong foundation of biotechnology in European nations like France and Germany as well as an increase in the number of research and development projects by biotechnological firms in the region.

Competitive Landscape

 Some of the prominent players in the global viral antigens market include 

• F. Hoffmann-La Roche AG.
• Bio-Rad Laboratories Inc.
• Creative Diagnostics
• Hologic Inc.
• Abbot Healthcare 
• LGC Limited
• Fujirebio Diagnostics Inc.
• Thermo Fisher Scientific Inc. 
• Cepheid 
• bioMerieux SA
• Qiagen 
• Diasorin
• Scienion AG
• Prospec-Tany Technogene Ltd.
• Siemens AG Grifols
• Eiken Chemical Co Ltd.
• Sequenom
• Advanced Biotechnology Inc.
• Diamedix Inc.

Strategic development

• In May 2020, the EUA for Quidel Corporation's Sofia 2 SARS Antigen FIA was approved by the U.S. FDA. It belongs to a brand-new class of tests that can soon find protein particles on or in the coronavirus. Patients' nasal cavities are sampled for the test to be performed.
• In May 2020, the U.S. FDA granted the SARS-CoV-2 Total Ab test by Bio-Rad Laboratories, a provider of premium products for the clinical diagnostics industry, EUA approval. A blood test is used to determine which antibodies the body produces in reaction to COVID-19.
• In July 2019, an American biotechnology company named Creative Diagnostics has launched a new line of viral antigens. The HBV, coronavirus, dengue, HAV, adenovirus, EV71, Ebola, and coxsackievirus will all be studied using this for biological research.

Frequently Asked Questions About This Report